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RNA-mediated mechanisms of disease pathogenesis in neurological disorders have been recognized in the context of certain repeat
expansion disorders. This RNA-initiated neurodegeneration may play a more pervasive role in disease pathology beyond the classic
dynamic mutation disorders. Here, we review the mechanisms of RNA toxicity and aberrant RNA processing that have been implicated in
ageing-related neurological disorders. We focus on diseases with aberrant sequestration of RNA-binding proteins, bi-directional tran-
scription, aberrant translation of repeat expansion RNA transcripts (repeat-associated non-ATG (RAN) translation), and the formation of
pathological RNA:DNA secondary structure (R-loop). It is likely that repeat expansion disorders arise from common mechanisms caused
by the repeat expansion mutations. However, the context of the repeat expansion determines the specific molecular consequences, leading
to clinically distinct disorders.
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Recent genome-wide studies have found that only 2% of
transcribed RNAs could be translated into proteins, making the
vast majority of transcripts “noncoding” (Encode Project
Consortium, 2012). Except for the RNAs involved in trans-
lation, such as rRNA and tRNA, other noncoding RNAs,
termed regulatory RNAs, can play a variety of roles in fine-
tuning gene expression (Erdmann et al., 2001). Among these
RNAs, microRNA (miRNA) (Filipowicz et al., 2008; Bartel,
2009; Krol et al., 2010) and long noncoding RNA (lncRNA)
(Batista and Chang, 2013; Fatica and Bozzoni, 2014) have
been explored extensively in recent years. Uncovering the
functions of these noncoding RNAs could significantly
improve our understanding of gene regulatory networks and
the molecular pathogenesis of human diseases.* Corresponding authors. Tel: þ1 404 727 3729, fax: þ1 404 727 3949.
E-mail addresses: duanranhui@sklmg.edu.cn (R. Duan); peng.jin@emory.
edu (P. Jin).
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1673-8527/Copyright 2014, Institute of Genetics and Developmental Biology, Chin
Limited and Science Press. Open access under CC BY-NC-ND license.Neurodegenerative disorders are caused by a wide range of
genetic mutations and epigenetic and environmental factors,
and repeat expansion has been recognized as the cause of
many neurodegenerative disorders (Nelson et al., 2013). A
common hallmark among neurodegenerative disorders is the
presence of insoluble protein-aggregates resistant to degrada-
tion by endogenous mechanisms, such as the ubiquitin-
proteasome system. This feature has led many research
groups to focus on protein-mediated processes in neuro-
degeneration (Nelson et al., 2013). However, the importance
of RNA-mediated mechanisms of disease pathogenesis in
neurological disorders has recently been recognized in the
context of certain trinucleotide repeat expansion disorders.
Here, we present an overview of the mechanisms of RNA
toxicity and aberrant RNA processing in neurological disor-
ders. Mechanistically, we focus on diseases with aberrant
sequestration of RNA-associated proteins (either by toxic
RNA species or other inclusions), the role of bi-directional
transcription in repeat expansion disorders, and aberrant
translation of repeat expansion RNA transcripts (repeat-asso-
ciated non-ATG (RAN) translation). There are commonese Academy of Sciences, and Genetics Society of China. Published by Elsevier
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expansion neurodegenerative diseases. It also seems that more
than one of these processes could contribute to the pathology
of any single RNA-mediated neurodegenerative disease.
SEQUESTRATION OF RNA-ASSOCIATED PROTEINS
The first clue that RNA-based mechanisms could underlie
neurodegeneration came with the discovery that the two forms
of myotonic dystrophy (DM1 and DM2) were caused by the
expansion of similar repetitive elements in two unrelated
genes, dystrophia myotonica protein kinase (DMPK ) and zinc
finger protein 9 (ZNF9) (Brook et al., 1992; Fu et al., 1992;
Liquori et al., 2001). Subsequent work has revealed a shared
mechanism in which the transcribed repeat elements bind
proteins important for RNA and DNA regulation, including
regulators of transcriptional activation and splicing, thereby
impeding their normal function (DM1 example, Fig. 1).
Because the repeat-containing RNA sequesters these proteins
to an extent that is not observed with wild-type alleles, this
mechanism is considered as an RNA-based gain-of-function
(RNA GOF). Since the DM1- and DM2-causing mutations
were discovered, multiple repeat expansion transcripts have
been shown to sequester key RNA-binding proteins, which
contribute to disease pathogenesis (Table 1).DM1 and DM2Discovered clinically over 100 years ago, DM1 is one of
the best-characterized RNA GOF neuromuscular disorders
(Amack et al., 1999; Mankodi et al., 2000; Miller et al., 2000;
Udd and Krahe, 2012). DM1 is an autosomal dominant con-
dition that results from the expansion of a CTG trinucleotideFig. 1. Mechanism of protein sequestration by mutant RNA in myotonic dystroph
The expanded CTG repeat within the 30-UTR of the DMPK gene is transcribed to
containing repeat sequestersMBNL1 and CUGBP1, interfering with their normal furepeat within the 30untranslated region (30UTR) of the DMPK
gene on chromosome 19 (Brook et al., 1992; Fu et al., 1992).
Normal alleles possess 534 CTG repeats and are stably
inherited. With increasing copies of the CTG repeat, the locus
becomes unstable during meiotic division, yielding full mu-
tations that range from 505000 repeats in size and cause
DM1. Clinical severity positively correlates with the
increasing CTG repeat number (Udd and Krahe, 2012).
The expanded CTG repeats are transcribed and found in
RNA foci in both DM1 patients and animal models (Taneja
et al., 1995; de Haro et al., 2006; Orengo et al., 2008).
These repeat expansion of DMPK transcripts form clusters
linked to the nuclear matrix (Taneja et al., 1995; David et al.,
1997). Mice in which 250-CTG repeats were inserted into an
unrelated gene also develop myotonia and myopathy, with the
transcripts retained in nuclei as discrete foci. This finding
demonstrated the central role of the CUG-containing RNA in
DM1 (Mankodi et al., 2000). Furthermore, a second mouse
model that carried a CTG-expanded human DMPK transgene
displayed histological, molecular, and electrophysiological
abnormalities identical to those observed in DM1 patients
(Seznec et al., 2001).
The expanded CUG repeat in DM1 transcripts is toxic, at
least partly, because it sequesters RNA-binding proteins
(RBPs). Muscleblind-like splicing regulator 1 (MBNL1) and
CUG-binding protein 1 (CUGBP1), two of the sequestered
RBPs, are splicing regulators essential for development (Lin
et al., 2006; Kalsotra et al., 2008). In DM1 patient cells,
MBNL1 co-localizes with the nuclear foci in which CUG
repeat expansion RNA is found, with concomitant splicing
aberrations evident (Miller et al., 2000; Fardaei et al., 2001;
Mankodi et al., 2001; Fardaei et al., 2002; Jiang et al., 2004;
Mankodi et al., 2005). The role of reduced MBLN1 functiony type I (DM1).
CUG repeats to produce a toxic gain-of-function (GOF) transcript. The CUG-
nctions. The blue box designates the location of the translation initiation codon.
Table 1
List of disease genes with dynamic mutations and potential RNA-mediated disease pathogenesis
Disease Gene Mutation Pathological mechanism
identified
Key sequestered protein
Myotonic dystrophy type I DMPK CTG repeat RNA GOF, protein GOF
(RAN translation)
MBNL1, CUGBP1
Myotonic dystrophy type II ZNF9 CCTG repeat RNA GOF e
Fragile X syndrome FMR1 >200 CCG repeats Epigenetic silencing of
FMR1, R-loops
e
Fragile X tremor ataxia syndrome FMR1 55e200 CCG repeats RNA GOF, protein GOF
(RAN translation), R-loops
hnRNP A2/B1, MBNL1,
cytoskeletal proteins,
heat shock proteins,
aB-crystallin, Pura, Sam68
Huntington’s disease-like 2 JPH3 CAG/CTG repeats RNA GOF, antisense
transcription, protein GOF
(RAN translation)
MBNL1
Frontotemporal degeneration/
amyotrophic lateral sclerosis
(C9ORF72 variant)
C9ORF72 GGGGCC repeats RNA GOF, antisense
transcription, protein GOF
(RAN translation), R-loops
hnRNPA3, hnRNPH,
ADARB2, Pura
Spinocerebellar ataxia type 8 AXTN8
ATXN8OS
CAG/CTG repeats RNA GOF, antisense
transcription, protein GOF
(RAN translation)
MBNL1
Spinocerebellar ataxia type 7 AXTN7 CAG repeat RNA GOF CRX
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exhibit muscle abnormalities, cataracts, and abnormal splicing
of chloride channel voltage sensitive 1 (CLCN1), and troponin
T type-2 (TNNT2) (discussed below), both of which have been
observed in DM1 patients (Kanadia et al., 2003). Furthermore,
the toxic effects of CUG repeat expansion transcripts can be
alleviated through alteration of MBNL1 expression level. In a
DM1 fly model, toxicity is suppressed by increasing MBNL1
expression, and enhanced when MBNL1 levels are reduced (de
Haro et al., 2006). Together, these findings imply that loss-of-
function of MBNL1 is sufficient to induce some of the aber-
rant splicing present in DM1 and contributes to the charac-
teristic symptoms of the disease.
Another contributor to the DM1 phenotype is CUGBP1.
Like MBNL1, this heterogeneous nuclear ribonucleoprotein
(hnRNP), binds specifically to CUG repeat-containing RNA
and regulates posttranscriptional RNA processing (Timchenko
et al., 1996). CUG repeat expansion activates the protein ki-
nase C (PKC) signaling pathway, leading to CUGBP1 hyper-
phosphorylation and stabilization, resulting in increased
CUGBP1 steady-state levels in DM1 myoblasts, skeletal
muscle, and heart tissues (Savkur et al., 2001; Timchenko
et al., 2001; Charlet et al., 2002; Dansithong et al., 2005;
Kuyumcu-Martinez et al., 2007; Wang et al., 2009). Animal
models of DM1 reflect human DM1 disease symptoms. In a
Drosophila model, increased CUGBP1 expression exacerbates
the disease phenotype (de Haro et al., 2006). Transgenic mice
overexpressing CUGBP1 in heart and skeletal muscle exhibit
characteristic muscle abnormalities associated with human
DM1 patients (Ho et al., 2005).
Many components of the DM1 disease phenotype are
correlated with specific mis-spliced genes. Sequestration of
MBNL1 and CUGBP1 by CUG repeat expansion transcriptsdisrupt their ability to regulate splicing of their targets,
explaining the intricacies of the DM1 phenotype (discussed
below). MBNL1 and CUGBP1 act antagonistically to regulate
the alternative splicing of insulin receptor (IR), chloride
channel voltage sensitive 1 (CLCN1), and troponin T type-2
(TNNT2) (Ho et al., 2004).
Removal of exon 11 of the IR gene is decreased in DM1
due to the increased activity of CUGBP1 and decreased ac-
tivity of MBNL1 (Savkur et al., 2001; Sen et al., 2010;
Grammatikakis et al., 2011). The aberrant regulation of IR
alternative splicing is hypothesized to contribute to insulin
resistance in DM1 (Savkur et al., 2001). CLCN1 is the main
chloride channel in muscle and regulates the electric excit-
ability of the skeletal muscle membrane. Abnormal inclusion
of CLCN1 exon 7A, resulting in loss of CLCN1 expression,
has been observed in DM1 patients, DM1 repeat expansion
mice (HSALR), and Mbnl1 knockout mice (Mankodi et al.,
2002; Kanadia et al., 2003). Furthermore, loss of CLCN1
function is a key contributor to myotonia in HSALR mice
(Mankodi et al., 2002). Overexpression of MBNL1 reverses
Clcn1 exon 7a exclusion in the HSALR mice (Kanadia et al.,
2006), further linking MBNL1 function with Clcn1 splice
regulation.
Put into its own disease category only 18 years ago, DM2
results from a CCTG repeat expansion in the first intron of the
ZNF9 gene (Liquori et al., 2001). DM1 and DM2 have nearly
identical symptoms; however, DM2 symptoms are less pro-
nounced, no congenital form of DM2 has been observed and
the pattern of muscle weakness in DM2 is clinically distinct
(Amato, 2012). As with DM1, nuclear foci containing
muscleblind proteins are observed in cells containing a DM2
repeat expansion (Fardaei et al., 2002). Similar patterns of
mis-spliced transcripts are observed in muscle of DM1 and
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muscle depleted of MBLN1 (Lin et al., 2006). It is not yet
clear whether differences in the expression patterns or cellular
interactors of the CCUG and CUG repeats are responsible for
the clinical differences between DM1 and DM2.FXS and FXTASFragile X syndrome (FXS), the most common monogenic
form of inherited intellectual disability, results from the
expansion of a CGG trinucleotide repeat within the 50 UTR of
the fragile X mental retardation 1 (FMR1) gene on the X
chromosome (Kremer et al., 1991; Oberle et al., 1991; Pieretti
et al., 1991; Verkerk et al., 1991). FXS presents in patients as
intellectual disability, hyperextensible joints, high arched
palate, and other characteristic physical features. Normal
FMR1 alleles contain 554 copies of the repeated sequence
and are quite stable. Premutation alleles with 55200 copies
of the CGG repeat, are unstable during germline transmission,
and the repeats can expand to a full mutation size of >200
repeats in one generation (Hagerman and Hagerman, 2002).
The full mutation transcript epigenetically silences the FMR1
gene via feedback dependent upon the association of the re-
peats in the mRNA transcript with the repeats in the DNA
(Colak et al., 2014). This is the first observation of a mutant
mRNA feeding back to regulate the gene from which it is
transcribed, but intriguingly, the dynamics of the premutation
transcript differ significantly, as seen in the pathogenesis of
fragile X-associated tremor/ataxia syndrome (FXTAS).
FXTAS is a late-onset neurodegenerative disorder with
distinct motor symptoms, which has been identified mainly
among male FMR1 premutation allele carriers (55200 CGG
repeats) (Hagerman and Hagerman, 2004). The clinical fea-
tures of FXTAS are gait ataxia, Parkinsonism, and progressive
neurodegeneration (Jacquemont et al., 2003). FXTAS patients
never present with FXS symptoms and vice versa. This is due
to the fact that FXTAS is an RNA GOF mechanism rather than
the FMR1 gene silencing seen in FXS.
In FXTAS, the FMR1 mRNA level is elevated up to 8-fold
over controls, while the protein level is normal to slightly
decreased (Tassone et al., 2000, 2007; Kenneson et al., 2001).
The major neuropathological hallmark of FXTAS is the
presence throughout the brain of eosinophilic, ubiquitin-
positive, intranuclear inclusions containing expanded FMR1
mRNA transcripts (Greco et al., 2002; Tassone et al., 2004; Li
and Jin, 2012). The frequency of intranuclear inclusions in
neurons and astrocytes and the clinical severity of the disease
are both correlated with CGG repeat length (Greco et al.,
2006). In a Drosophila FXTAS model expressing 90 CGG
repeats, the repeat-containing RNA is sufficient to cause
progressive neurodegeneration in the eye and to induce the
formation of inclusions. The inclusions are HSP70- and
ubiquitin-positive, and overexpression of HSP70 suppresses
the neurodegeneration phenotype (Jin et al., 2003). Mouse
models of FXTAS, carrying the human premutation allele, also
have elevated Fmr1 mRNA levels and ubiquitin-positive
intranuclear inclusions of HSP40. In mouse models ofdisease, the number and the size of the inclusions in FXTAS
increase over time, consistent with the pathology seen in pa-
tients (Willemsen et al., 2003). In human primary neural
progenitor cells and established neural cell lines, a knocked-in
88 CGG repeat-containing FMR1 allele induces the formation
of intranuclear inclusions, which decrease cell viability and
disrupt normal lamin A/C architecture within the nucleus
(Arocena et al., 2005). Additionally, mass-spectrometry anal-
ysis of FXTAS inclusions have identified 20 proteins including
RBPs hnRNPA2/B1 and MBNL1, intermediate filament pro-
teins lamins A/C, heat shock proteins HSP70 and HSP27, and
aB-crystallin (Iwahashi et al., 2006).
Similar to the toxic RNA effects documented in myotonic
dystrophy, sequestration of RBPs contributes to the pathologic
process in FXTAS. These RBPs normally participate in tran-
scriptional regulation, RNA transport, RNA splicing, and
regulation of microRNAs. One of these sequestered RBPs is
Pura. In mice, the loss of Pura leads to tremor, gait distur-
bances, and early loss of viability (Jin et al., 2007). The pre-
viously discussed RBP CUGBP1 also interacts with CGG
repeat-containing mRNA in an hnRNP A2/B1-dependent
manner. Overexpression of either hnRNP A2/B1 or CUGBP1
in a 90 CGG Drosophila model of FXTAS suppresses the
neurodegeneration phenotype (Sofola et al., 2007), further
supporting the role of RBP sequestration in FXTAS.
Several additional RBPs are sequestered by CGG-
containing RNAs, resulting in downstream mis-regulation of
gene expression. Another factor whose expression is regulated
by hnRNP A2/B1 is miR-277. In turn, this microRNA regu-
lates the expression of Drep-2 and Vimar, which are involved
in apoptosis and mitochondrial function, respectively (Tan
et al., 2012). SAM68, a splicing modulator whose absence
in the mouse leads to motor dysfunction, is also sequestered by
CGG-containing mRNAs, which in turn leads to altered
splicing of SMN2 and ATP11 B. Finally, the double-stranded
RNA-binding protein DGCR8 and its partner, DROSHA, are
found within CGG RNA aggregates. As a result, the pro-
cessing of several microRNAs is reduced in the presence of a
repeat expansion (Sellier et al., 2010).HDL2Huntington’s disease-like 2 (HDL2) is an autosomal dominant,
progressive, neurodegenerative disorder that is caused by
CAG/CTG repeat expansion within exon 2A of the
junctophilin-3 (JPH3) gene (Holmes et al., 2001; Margolis
et al., 2001). In humans, the wild-type allele possesses 628
copies of the repeat whereas the disease allele has 4059
repeats. Clinically and pathologically, HDL2 is similar to
Huntington’s disease (HD), with symptoms including chorea,
dystonia, dementia and death (Margolis et al., 2001; Margolis
et al., 2004; Greenstein et al., 2007; Rudnicki et al., 2008).
In the brains of affected patients, RNA foci containing the
expanded CUG repeat transcripts and MBNL1 resemble those
observed in DM1 patients. In HEK293 or HT22 cells, over-
expression of JPH3 exon 2A containing 53 CTG repeats leads
to the formation of MBNL1-containing RNA foci and to cell
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the MBNL1 targets, microtubule associated protein tau
(MAPT) and amyloid precursor protein (APP). These findings
indicate the expanded CUG repeat exerts its toxicity in a
similar fashion to DM1, and potentially to FXTAS, via
sequestration of MBNL1, leading to disruption of alternative
splicing of specific MBNL1 pre-mRNA targets (Rudnicki
et al., 2007).FTD and ALSA hexanucleotide repeat (GGGGCC, G4C2) expansion (HRE)
within the first intron of the chromosome 9 open reading frame
72 (C9ORF72) gene has been identified as the most common
genetic cause of frontotemporal degeneration (FTD) and
amyotrophic lateral sclerosis (ALS) (DeJesus-Hernandez
et al., 2011; Renton et al., 2011). This expansion is present
in 5%15% of sporadic FTD and ALS patients, but it ac-
counts for 20%80% of familial FTD and ALS patients in the
North American and European populations (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Stepto et al.,
2014).
Normal human C9ORF72 alleles have 223 repeats,
whereas FTD/ALS patients may have thousands of copies of
the G4C2 repeat (DeJesus-Hernandez et al., 2011; Rutherford
et al., 2012). ALS and FTD are distinct diseases with
significant overlap among affected patients. FTD results from
the selective degeneration of neurons in the frontal and tem-
poral lobes, leading to the progressive deterioration of lan-
guage skills and distinct personality changes (Rademakers
et al., 2012). ALS is characterized by the loss of upper
motor neurons in the motor cortex and lower motor neurons in
the brainstem and spinal cord, causing muscle atrophy and
spasticity (Giordana et al., 2011; Robberecht and Philips,
2013). Almost 50% of ALS patients have cognitive or
behavioral impairment characteristic of FTD, and up to 50%
of FTD patients develop motor neuron dysfunction charac-
teristic of ALS (DeJesus-Hernandez et al., 2011; Giordana
et al., 2011; Gendron et al., 2014).
RNA-mediated toxicity is one of the processes implicated
in C9ORF72 expansion in FTD/ALS. The repeat-containing
RNA is sufficient to induce RNA foci in a Drosophila
model, and this is associated with cellular toxicity in the eye
and motor neurons (Lee et al., 2013; Xu et al., 2013). RNA
foci containing the G4C2 expanded repeats are also present in
neurons of the frontal cortex, cerebellum, hippocampus and
spinal cord, as well as in non-neuronal cells, such as lym-
phoblasts, fibroblasts, and astrocytes of C9ORF72-related
FTD and ALS patients (DeJesus-Hernandez et al., 2011;
Lagier-Tourenne et al., 2013; Mizielinska et al., 2013). The
frequency of nuclear RNA foci in the frontal cortex inversely
correlates with the age at onset of FTD in these patients
(Mizielinska et al., 2013).
Studies of repeat-expanded C9ORF72 from patient-derived
induced pluripotent stem cells, transfected cells, and a
Drosophila model of FTD/ALS have identified several RBPs
sequestered by G4C2 repeats, including heterogenous nuclearribonucleoprotein 3 (hnRNPA3), heterogenous nuclear ribo-
nucleoprotein H (hnRNPH), RNA-specific adenosine deami-
nase B2 (ADARB2) and Pura. For each of these interactions,
additional experiments have documented secondary effects of
this sequestration, including cellular redistribution of the RBP
(Mori et al., 2013a), differences in mRNA splicing patterns
(Lee et al., 2013), increases in the glutamate susceptibility of
neurons (Donnelly et al., 2013), and reduced neuronal cell
viability (Xu et al., 2013). Manipulation of the expression
level of these RBPs influences several of these effects, sup-
porting the idea that RBP sequestration in RNA foci contrib-
utes to the observed cellular phenotypes (Donnelly et al.,
2013; Lee et al., 2013; Xu et al., 2013).SCA7Positional cloning of spinocerebellar ataxia type 7 (SCA7)
revealed the cause to be a CAG/polyglutamate repeat expan-
sion in exon 1 of the Ataxin7 (ATXN7) gene (Davis et al.,
1997). SCA7 was distinguished from the other spinocer-
ebellar ataxias by the presence of retinal degeneration in
addition to ataxia and cerebellar degeneration. Specifically,
cone cell degeneration followed by rod cell degeneration
eventually leads to total blindness. Expression of CAG-repeat
expansion mRNA disrupts the transcriptional activity of cone-
rod homeobox protein (CRX) through sequestration of the
transcription factor, leading to down-regulation of genes crit-
ical for photoreceptor function including the color opsins and
rhodopsin (La Spada et al., 2001).
BI-DIRECTIONAL TRANSCRIPTION
Bi-directional transcription is a pervasive feature of mamma-
lian genomes, and a growing number of eukaryotic genes are
being found to have natural antisense transcripts (Yelin et al.,
2003; He et al., 2008; Faghihi and Wahlestedt, 2009). These
antisense RNAs regulate multiple levels of gene expression,
including transcription, RNA maturation, RNA transport, RNA
stability, and translation (Knee and Murphy, 1997; Hastings
et al., 2000; Li and Murphy, 2000). As detailed below, evi-
dence is accumulating that antisense transcripts contribute to
neurodegeneration in repeat expansion disorders.SCA8Spinocerebellar ataxia type 8 (SCA8) is a progressive neuro-
degenerative disorder caused by a CTG/CAG repeat expansion
located in the 30 UTR of the Ataxin 8 (AXTN8) gene on
chromosome 13. SCA8 is characterized by ataxia and marked
cerebellar atrophy (Koob et al., 1999; Day et al., 2000). In the
past, SCA8 was thought to be caused by an RNA GOF
mechanism because the only detected mutation was a CUG
expansion in a noncoding transcript (Koob et al., 1999;
Mutsuddi et al., 2004). However, in a BAC transgenic
mouse model expressing human AXTN8 with an 116-CTG
repeat expansion, both CUG- and CAG-containing expansion
transcripts were identified in the central nervous system,
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et al., 2006) (SCA8 example, Fig. 2). This bi-directional
transcription of the SCA8 expansion yields RNA from the
Ataxin 8 opposite strand (ATXN8OS ) as well as the Ataxin 8
coding strand (ATXN8) (Moseley et al., 2006). Both the CUG-
containing ATXN8OS and CAG-containing ATXN8 transcripts
are translated into proteins that are likely to participate in the
pathologic process.FXTASAn antisense transcript that encompasses the FMR1 CGG
repeat expansion has been implicated in FXTAS. This widely
expressed transcript, ASFMR1, is alternatively spliced, poly-
adenylated and exported to the cytoplasm. Transcription of
ASFMR1 can be initiated either at the bi-directional FMR1
promoter or at another antisense promoter located in intron 2
of FMR1; however, the latter is the major promoter utilized in
cells with a premutation allele of the CGG repeat in FMR1.
Similar to FMR1, ASFMR1 transcript levels are elevated in
premutation carriers and absent in those with a full mutation.
Furthermore, alternative splicing of the antisense transcript is
influenced by the presence of a premutation allele (Ladd et al.,
2007).
There is another, probably independent antisense transcript
in the vicinity. FMR4, a primate-specific noncoding RNA
transcript, is transcribed upstream of FMR1. Although it is not
antisense to FMR1 in the sense that they don’t overlap, FMR4
appears to use the bi-directional FMR1 promoter, and as withFig. 2. Mechanism of bi-directional transcription in SCA8.
Translation of the CAG-repeat expansion RNA produces polyGln peptides that a
containing RNA that could sequester MBNL1 protein and lead to the formation othe other transcripts mentioned, its expression is up-regulated
in premutation carriers and absent in full mutation carriers.
FMR4 expression regulates mammalian cell proliferation in
culture by inhibiting apoptosis (Khalil et al., 2008). Additional
studies are needed to reveal the role of antisense transcription
products in FXTAS.HDL2Studies in a BAC transgenic mouse model of HDL2 have
demonstrated that a novel promoter drives the transcription of
an expanded CAG repeat-containing transcript antisense to
JPH3, and that this transcript is translated into a
polyglutamine-containing protein (Wilburn et al., 2011).
These mice manifest motor, neuropathological and molecular
phenotypes characteristic of HDL2 and accumulate nuclear
inclusions that contain polyglutamine (polyQ) proteins (dis-
cussed below). Interestingly, silencing of mutant JPH3-CUG
repeat expansion transcripts, by knock-in of a premature stop
codon gene, does not suppress the expression or translation of
the antisense transcript (Wilburn et al., 2011). Thus, HDL2
appears to result at least partially from bi-directional tran-
scription at the expanded repeat in the JPH3 gene.FTD and ALSSeveral studies have revealed bi-directional transcription of
the expanded C9ORF72 G4C2 repeat in C9ORF72 FTD/ALS
(Gendron et al., 2013; Lagier-Tourenne et al., 2013;ggregate. Transcription of the reverse strand (ATXN8OS ) produces a CUG-
f RNA aggregation foci.
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2013). The Mori group detected elevated levels of antisense
transcripts containing the C4G2 repeat in affected patients
(Mori et al., 2013b). Expression of the antisense repeat 66
C4G2, but not 2 C4G2, in HEK293T cells results in the for-
mation of nuclear RNA foci, as detected by RNA FISH.
Although varying in number between individuals, antisense
RNA foci are also present in the brain and spinal cord of
C9ORF72 FTD/ALS patients (Gendron et al., 2013). These
antisense foci are present in multiple cell types, including
astrocytes, microglia and oligodendrocytes (Mizielinska et al.,
2013). In addition, sense and antisense RNA foci accumulate
in the blood of C9ORF72 patients, making them the potential
biomarkers of C9ORF72 FTD/ALS (Zu et al., 2013). Anti-
sense oligonucleotide (ASO) treatment targeting the sense
RNA does not lower the frequency of antisense RNA foci,
suggesting that antisense RNA transcription is independent of
sense transcription, as observed in HDL2 (Lagier-Tourenne
et al., 2013). The identification of both sense and antisense
RNA foci in C9ORF72 patients suggests that bi-directional
transcription is a pathologic feature of C9ORF72 FTD/ALS,
but further insight is required to dissect the contribution of bi-
directional transcription to C9ORF72 FTD/ALS.RAN TRANSLATION
RAN translation occurs independent of the canonical AUG
codon and has been demonstrated in vitro and in vivo (Hann
et al., 1988; Kozak, 1989; Peabody, 1989). Recent studiesFig. 3. Mechanisms of toxic protein production in SCA8 through RAN and norma
Note that the production of 9 toxic products is possible (numbered). From the nativ
containing polypeptide (2) are produced via the normal initiating codon. The repe
products through translation within each reading frame (3e5). RAN translation alhave confirmed that despite the absence of an upstream AUG
codon, RAN translation of repeat expansion tracks can occur
in all 30 reading frames from both the sense and antisense
transcripts (SCA8 example, Fig. 3). Only discovered to play a
role in SCA8 and DM1 in 2011, RAN translation has the
potential to contribute to a shared pathogenic mechanism for
many repeat expansion disorders (Zu et al., 2011).SCA8 and DM1RAN translation of the CAG expansion of the antisense
transcript ATXN8OS into a polyQ-containing polypeptide had
been observed in SCA8 (Zu et al., 2011). This had been
determined in a Drosophila model to be sufficient to cause
polyQ-positive inclusions and a neurodegenerative phenotype
(Marsh et al., 2000). To investigate the role of polyQ in SCA8,
Zu et al. (2011) created an ATXN8 minigene from which they
removed the only ATG initiation codon within the CAG
expansion of ATXN8OS. When transfected into
HEK293T cells, the mutant minigene still expressed polyQ-
containing protein. Additional experiments demonstrated that
RAN translation across the expanded CAG repeats occurs in
all reading frames and in addition to polyQ produces poly-
alanine (polyAla), and polyserine (polySer) proteins. PolyAla
inclusions occur in cerebellar Purkinje cells in both SCA8
patients and SCA8 BAC transgenic mice (Zu et al., 2011).
In DM1 polyQ nuclear aggregates are present in cardiac
myocytes and leukocytes of DM300 transgenic mice, and in
blood, skeletal muscle, and myoblasts from DM1 patients (Zul translation.
e transcript, the toxic repeat expanded RNA (1) and its corresponding polyGln
at expanded RNA can undergo RAN translation to produce 3 separate protein
so occurs to the bi-directionally transcribed RNA (6e9).
480 R. Duan et al. / Journal of Genetics and Genomics 41 (2014) 473e484et al., 2011). PolyAla and polySer have also been observed but
a direct link between translation of these species and patho-
genicity has yet to be determined.FXTASRAN translation in FXTAS was described by Todd et al.
(2013). It was identified in a Drosophila FXTAS model in
which the 50UTR of FMR1 containing 90 CGG repeats was
placed upstream of the gene of green fluorescent protein
(GFP). This produced a high-molecular weight GFP fusion
protein containing a stretch of polyglycine (polyGly) at the N-
terminus. It was shown that CGG repeats could also initiate
RAN translation in the polyAla-producing reading frame,
albeit to a lower extent. The polyGly-containing protein can be
found in ubiquitin-positive inclusions in the fly model and in
the brains of patients with FXTAS. Although RAN translation
in the polyGly reading frame occurs even at normal CGG
repeat lengths, inclusion formation increases as the CGG
repeat length gets longer, and in a cell culture system, in-
clusions were not present with a 30 CGG allele knock-in
(Todd et al., 2013).FTD and ALSFig. 4. The structure of R-loop.
RNA polymerase II (green pentagon) transcribes through repeat expansions
(orange DNA strands) producing the repeat expanded RNA transcripts (blue
strand). The repeat-containing RNA preferentially pairs with the noncoding
DNA strand, displacing the normal dsDNA base pairing and causing down-
stream epigenetic modifications that lead to increased gene silencing.RAN translation in C9ORF72 FTD/ALS was demonstrated by
multiple groups independently (Gendron et al., 2013; Mori
et al., 2013b; Zu et al., 2013). Both sense and antisense
transcripts of the expanded C9ORF72 G4C2 repeat are RAN
translated. RAN translation of sense transcripts that contain
G4C2 repeats results in the production of poly-Gly-Ala (GA),
poly-Gly-Arg (GR) and poly-Gly-Pro (GP). RAN translation
of antisense transcripts that contain C4G2 repeats generates
poly-Pro-Arg (PR), poly-Pro-Ala (PA) and poly-Pro-Gly (PG).
Similar to the abundance and distribution of the p62-positive/
TDP43-negative inclusions pathognomonic for C9ORF72
FTD/ALS, both cytoplasmic and intranuclear inclusions con-
taining poly-GA, and to a lesser extent poly-GR and poly-GP,
are present in the cerebellum, hippocampus and other brain
regions of these patients (Ash et al., 2013; Mori et al., 2013b).
These translation products have been found to co-aggregate
with p62-positive/TDP43-negative inclusions (Mori et al.,
2013b, 2013c). Targeting the G4C2 repeat expansion RNA in
C9ORF72 induced pluripotent stem cell differentiated neurons
using ASOs mitigated the susceptibility to excite-toxicity, led
to large reductions in RNA foci and RBP aggregation, and
normalized gene expression (Donnelly et al., 2013). However,
the sense RAN product poly-GP could still be detected and
therefore is unlikely to play a role in these phenotypes. In
contrast, the antisense RAN proteins poly-PR and poly-GP are
intrinsically toxic to transfected HEK293T cells (Zu et al.,
2013). It will be significant to elucidate how the different
DPR RAN translation products contribute to the phenotypes of
C9ORF72 FTD/ALS. An additional layer of complexity is that
the production of each unique species (poly-Ala, poly-Ser,
etc.) is dependent on the length of the repeat in a CAG
repeat model (Pearson, 2011).R-LOOP
Discovered to play a role in repeat expansion diseases very
recently, R-loops, which are composed of nascent RNA-
noncoding DNA hybrids together with the resulting displaced
ssDNA, are a novel mechanism by which the structural changes
induced at repeat expansion loci during transcription induce
pathology (Fig. 4) (Aguilera and Garcia-Muse, 2012). Bio-
physically, the formation of R-loops at repeat expansion loci can
be attributed to increased thermodynamic stability of RNA-
DNA hybrids in comparison to dsDNA. Interesting, R-loops
play roles in many normal cellular processes including class-
switch recombination in B-lymphocytes.FTD and ALSAt the C9ORF72 locus, a DNA-RNA hybrid folds into a
stable G-quadruplex secondary structure and induces the
formation of R-loops, which impair RNA polymerase proc-
essivity in the expanded repeat region. This results in an
accumulation of short, repeat-containing, abortive transcripts
with a loss of full-length transcripts both in vitro and in the
motor cortex and cervical spinal cord of C9ORF72 FTD/
ALS patients. Nucleolin, an essential nucleolar protein,
preferentially associates with G-quadruplexes and is local-
ized to RNA foci in C9ORF72 FTD/ALS patient cells,
causing disrupted rRNA processing, reduced maturation of
ribosomes and consequent chronic nucleolar stress. This
demonstrates that structural conformations in both the
C9ORF72 HRE DNA and RNA could serve as fundamental
pathogenic determinants of C9ORF72 FTD/ALS (Haeusler
et al., 2014).FXTAS and Friedreich ataxiaVery recently, R-loop formation was demonstrated at the
FMR1 locus for both premutation alleles and full mutation
481R. Duan et al. / Journal of Genetics and Genomics 41 (2014) 473e484alleles (Loomis et al., 2014). This was confirmed by Groh
et al. (2014), who also found that R-loops are enriched over
FXN intron 1 in cells with Friedreich ataxia-associated repeat
expansions, compared to control cells. The formation of R-
loops precedes the presence of heterochromatin marks but
correlates with epigenetic silencing of FXN and FMR1 and
may be involved in the recruitment of enzymes involved in
heterochromatinization. Inhibition of DNA-topoisomerase at
the FXN locus (the causal gene in Friedreich ataxia) increases
R-loop formation and is positively correlated with gene
silencing (Groh et al., 2014). Together, these data may indicate
that the formation of increased numbers of R-loops and the
corresponding increase in silencing epigenetic marks may
reduce expression of the corresponding disease genes. Taken
in the context of the unique dynamics of the premutation and
full mutation alleles present in FXTAS and FXS, respectively,
this indicates that the degree of R-loop burden at the FMR1
locus may be the determining factor in whether the gene is
silenced or not, potentially explaining the findings in Colak
et al. (2014) where the RNA-DNA interaction was required
for epigenetic silencing of the FMR1 locus.CONCLUDING REMARKS
Emerging work discussed here suggest that the involvement of
RNAs in human neurological diseases could be far more
prevalent than previously appreciated, and untangling the
RNA-mediated disease pathogenesis could vastly improve our
understanding and treatment of these disorders. RNA toxicity
could be mediated by several parallel mechanisms, including
sequestration of RNA-binding proteins, which activates
abnormal signaling cascades; aberrant expression of antisense
transcripts, which has deleterious consequences at multiple
levels; accumulation of mRNA/protein-aggregates, which may
have detrimental effects on cellular homeostasis; and an
altered microRNA pathway, which influences target(s) tran-
scription or translation. Besides RNA toxicity, the recently
discovered novel mechanisms, such as RAN translation and
R-loops, could contribute to disease pathogenesis as well.
Future studies are needed to elucidate the mechanism by
which dysregulated RNA functional motifs can affect regu-
latory domains and compromise its ability to interact with
other molecules, thereby contributing to the pathogenesis of
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